Treatment for the recurrent tumor included stereotactic radiotherapy with a dose of 25 Gy in 5 daily fractions prescribed to the 80% isodose line, followed by combination targeted therapy with BRAF/MEK inhibitors (Dabrafenib, Trametinib). Here, BRAF is linked to neoplasm.